$Esperion Therapeutics (ESPR.US)$The recent analyst note from Jeff sugest Esperion might sell the entire rights for Bempedoic Acid. Fair valuation on the rights would be above $1.5 billion, based on future milestones $900 million, future royalties & patents, the current formulation patent has exp date Dec 2031. The potential yearly sales in the U.S could reach $4 billion by 2027. Esperion could also partner in the U.S . Keep an...
Consumer spending at hardline and broadline retailers likely improved in the third quarter on a sequential basis while Home Depot$Home Depot (HD.US)$, Lowe's$Lowe's Companies (LOW.US)$, Five Below$Five Below (FIVE.US)$and Walmart$Walmart (WMT.US)$all seem set to beat comparable sales forecasts for the period, Truist Securities said Monday. The firm raised price targets for several stocks in its retail coverage unive...
Morning Movers Gapping up $Goldman Sachs (GS.US)$stock increased by 3.0% after the investment bank exceeded third-quarter expectations, driven by strong performance in its Global Banking & Markets division which generated quarterly net revenues of $8.55 billion. $Bank of America (BAC.US)$stock advanced 2.2% following earnings that beat expectations, supported by higher investment banking fees, despite a slight year-on-year dr...
Esperion could also partner in the U.S .
Keep an...
Running out of patience.. sold for some coffee money.
not selling some till 13 50
The firm raised price targets for several stocks in its retail coverage unive...
Gapping up
$Goldman Sachs (GS.US)$ stock increased by 3.0% after the investment bank exceeded third-quarter expectations, driven by strong performance in its Global Banking & Markets division which generated quarterly net revenues of $8.55 billion.
$Bank of America (BAC.US)$ stock advanced 2.2% following earnings that beat expectations, supported by higher investment banking fees, despite a slight year-on-year dr...
No comment yet